Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.38 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.37 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 2/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | IDH1 | O75874 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3927570 | 0.89 | RAB9A (0.38) | RAB9ANPC1SMN1; SMN2TRPV1PKM | |
| SCHEMBL4119234 | 0.82 | KMT2A (0.41) | RAB9AANO1MAP2K4PKMMAPK1 | |
| SCHEMBL4117392 | 0.76 | JAK2 (0.55) | RAB9AMAPK1NAMPT | |
| SCHEMBL1456541 | 0.74 | WDR5 (0.48) | RAB9ANPC1SMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL3935784 | 0.72 | KMT2A (0.40) | RAB9AANO1PKMMAPK1KMT2A | |
| SCHEMBL18108638 | 0.69 | KDM4E (0.46) | RAB9ANPC1SMN1; SMN2MAP2K4MAPK1 | |
| SCHEMBL923468 | 0.69 | CA1 (0.45) | NPC1SMN1; SMN2MAP2K4KMT2AIDO1 | |
| SCHEMBL3517026 | 0.67 | MAP2K4 (0.46) | RAB9ANPC1MAP2K4PKMMAPK1 | |
| SCHEMBL29746805 | 0.66 | BCL6 (0.38) | RAB9ANPC1MAP2K4KMT2AALDH1A1 | |
| SCHEMBL30070444 | 0.66 | BCL6 (0.38) | RAB9ANPC1MAP2K4KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2040701-B1 | AMINOINDAZOLE UREA DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-03-18 | — | — | EP | disclosed |
| US-8207210-B2 | Aminoindazolylurea derivatives | MERCK PATENT GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| US-8207210-B2 | Aminoindazolylurea derivatives | MERCK PATENT GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| US-8207210-B2 | Aminoindazolylurea derivatives | MERCK PATENT GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| US-20090253767-A1 | AMINOINDAZOLYLUREA DERIVATIVES | MERCK PATENT GESELLSCHAFT (DE) | 2009-10-08 | — | — | US | disclosed |
| US-20090253767-A1 | AMINOINDAZOLYLUREA DERIVATIVES | MERCK PATENT GESELLSCHAFT (DE) | 2009-10-08 | — | — | US | disclosed |
| US-20090253767-A1 | AMINOINDAZOLYLUREA DERIVATIVES | MERCK PATENT GESELLSCHAFT (DE) | 2009-10-08 | — | — | US | disclosed |
| WO-2008009335-A2 | AMINOINDAZOLE UREA DERIVATIVES | MERCK PATENT GMBH (DE) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253767-A1 | AMINOINDAZOLYLUREA DERIVATIVES | SGK2, SGK1, SGK3 | RAB9A 3528/4885NPC1 3287/4885SMN1; SMN2 4645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.